PD-136,450: A CCK2 (gastrin) receptor antagonist with antisecretory, anxiolytic and antiulcer activity

Molecular and Cellular Biochemistry

Volumn 252, Issue 1-2, 2003, Pages 83-90

  Bastaki, S M A ^a   Hasan, M Y ^a   Chandranath, S I ^a   Schmassmann, A ^b   Garner, A ^c  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b UNIVERSITY OF BERN   (Switzerland)

^c HOPE HOSPITAL   (United Kingdom)

Author keywords

CCK1; CCK2; Dimaprit; L 364,718; L 365,260; Omeprazole; PD 136,450; Pentagastrin

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; ALCOHOL; AMINOPHENAZONE; ANTIULCER AGENT; ANXIOLYTIC AGENT; CARBON 14; CHOLECYSTOKININ RECEPTOR; DEVAZEPIDE; DIAZEPAM; DIMAPRIT; GASTRIN; GASTRIN ANTAGONIST; OMEPRAZOLE; PD 136 450; PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR; UNCLASSIFIED DRUG;

ANESTHESIA INDUCTION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROTECTION; CONSCIOUSNESS; CONTROLLED STUDY; DARKNESS; DOSE RESPONSE; DRUG ACTIVITY; DRUG SELECTIVITY; FEMALE; INHIBITION KINETICS; LATENT PERIOD; LIGHT; MALE; MEDICAL ASSESSMENT; MOUSE; NONHUMAN; PANCREAS SECRETION; PEPTIC ULCER; RABBIT; STOMACH ACID SECRETION; STOMACH GLAND; STOMACH HEMORRHAGE; STOMACH MUCOSA; TIME; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTI-ULCER AGENTS; FEMALE; GASTRIC ACID; INDOLES; MALE; PANCREAS; PHENETHYLAMINES; RABBITS; RATS; RECEPTOR, CHOLECYSTOKININ B;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0141616569     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025566919581     Document Type: Article

References (48)

1. Kovacs TOG, Walsh JH, Maxwell V, Wong HC, Azuma T, Katt E: Gastrin is a mediator of gastric phase of acid secretion in dogs: Proof by monoclonal antibody neutralization. Gastroenterol 97: 1406-1413, 1989
2. Lloyd KC, Raybould HE, Tache Y, Walsh JH: Role of gastrin, histamine, and acetylcholine in the gastric phase of acid secretion in anaesthetized rats. Am J Physiol 262: G747-G755, 1992
3. Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter JC, Pinnock RD, Woodruff GN: Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 87: 6728-6732, 1990
4. Horwell DC, Hughes J, Hunter JC, Pritchard MC, Richardson RS, Roberts E, Woodruff GN: Rationally designed 'dipeptoid' analogue of CCK, α-methyl tryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties. J Med Chem 34: 404-414, 1991
5. Padia JK, Field M, Hinton J, Meecham K, Pinnock R, Rotl BD, Singh L, Suman-Chauhan N, Trivedi BK, Webdale L: Novel non-peptide CCK-B antagonists: Design and development of quinazolinone derivatives as potent, selective and orally active CCK-B antagonists. J Med Chem 41: 1042-1049, 1998
6. Watson S, Durrant L, Elston P, Moore D: Inhibitory effects of the gastrin receptor antagonists (L-365,260) on gastrointestinal tumor cells. Cancer 68: 1255-1260, 1991
7. Eissele R, Patberg H, Koop H, Krack W, Lorenz W, McKnight AT, Arnold R: Effect of gastrin receptor blockade on endocrine cells in rats during achlorhydria. Gastroenterology 103: 1596-1601, 1992
8. Fontana MG, Donata F, Villanacci V, Ghirardi M, Moneghini D, Di Betta E, Salerni B: Inhibitory effect of a gastrin receptor antagonist, CR2945, on 1,2-dimethylhydrazine-induced colorectal cancer in mice. Eur Surg Res 31: 406-411, 1999
9. Schmassmann A, Reubi JC: Cholecysokinin-B/gastrin receptors enhance wound healing in the rat gastric mucosa. J Clin invest: 106: 1021-1029, 2000
10. Innis RB, Snyder SN: Distinct cholecystokinin receptor in brain and pancreas. Proc Natl Acad Sci 77: 6917-6921, 1980
11. Ohlsson B, Borg K, Rehfeld JF, Ihse I, Axelson J: The effect of intermittent injections of CCK-8S and CCK-A receptor antagonist devazepide on cell proliferation in exocrine rat pancreas. Int J Pancreatol 24: 211-218, 1998
12. Wang L, Cardin S, Martinez V, Tache Y, Lloyd KC: Duodenal loading with glucose induces fos expression in rat brain: Selective blockade by devazepide. Am J Physiol 277: R667-R674, 1999
13. De Dios I, Urunuela A, Orfao A, Manso MA: Cholecystokinin antagonist L-364,718 induces alterations in acinar cells that prevent improvement of acute pancreatitis induced by obstruction. Dig Dis Sci 47: 1800-1809, 2002
14. Hill DR, Campbell NJ, Shaw TM, Woodruff GN: Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide CCK antagonists. J Neurosci 7: 2967-2976, 1987
15. Hill DR, Shaw TM, Woodruff GN: Species differences in the localization of 'peripheral' type cholecystokinin receptors in rodent brain. Neurosci Lett 79: 286-298, 1987
16. Josselyn SA, Franco VP, Vaccarino FJ: Devazepide, a CCKA receptor antagonist, impairs the acquisition of conditioned reward and conditioned activity. Psychopharmacologia 123: 131-143, 1996
17. Gracey DJ, Bell R, King DJ: PD-136450, a cholecystokinin(B) antagonist, enhances latent inhibition in the rat. Pharmacol Biochem Behav 65: 459-463, 2000
18. Lotti VJ, Chang RSL: A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Eur J Pharmacol 162: 273-280, 1989
19. Huang SC, Zhang L, Chiang HCV, Wank SA, Maton PN, Gardner JD, Jensen RT: Benzodiazepine analogues, L-365,260 and L-364,718 as gastrin and pancreatic CCK receptor antagonists. Am J Physiol 257: G169-G174, 1989
20. Hayward NJ, Harding M, Lloyd SAC, McKnight AT, Hughes J, Woodruff GN: The effect of CCK-B/gastrin antagonists on stimulated gastric acid secretion in the anaesthetized rat. Br J Pharmacol 104: 973-997 1991
21. Nishida A, Takinami Y, Yuki H, Kobayashi A, Akuzawa S, Kamato T, Ito H, Yamano M, Nagakura Y, Miyata K: YM022 {(R)-1-[2,3-dihydro-1-(2′-methylphenacyl)-2-oxo-5-phenyl-1H-1,4 -benzodiazepin-3-yl]-3-(methylphenyl) urea}, a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats. J Pharmacol Exp Ther 270: 1256-1261, 1994
22. Nishida A, Yuki H, Tsutsumi R, Miyata K, Kamato T, Ito H, Yamano M, Honda K: L-365,260, a potent CCK-B/gastrin receptor antagonist, suppresses gastric acid secretion induced by histamine and bethanechol as well as pentagastrin in rats. Jpn J Pharmacol 58: 137-145, 1992
23. Murphy MG, Sytnik B, Kovacs TOG, Mertz H. Ewanik D, Shingo S, Lin JH, Gertz BJ, Walsh JH: The gastrin-receptor antagonist L-365,260 inhibits stimulated acid secretion in humans. Clin Pharmacol Ther 54: 533-539, 1993
24. de Montigny C: Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch Gen Psychiatry 46: 511-517, 1989
25. Pande AC, Greiner M, Adams JB, Lydiard RB, Pierce MW: Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder. Biol Psych 46: 860-862, 1999
26. Schmassmann A, Garner A, Flogerzi B, Hasan MY, Sanner M, Varga L, Halter F: Cholecystokinin type B receptor antagonist PD-136,450 is a partial agonist in the stomach and a full agonist in the pancreas of the rat. Gut 35: 270-274, 1994
27. Trevedi BK, Padia JK, Holmes A, Rose S, Wright DS, Hinton JP, Pritchard MC, Eden JM, Kneen C, Webdale L, Suman-chauhan N, Boden P, Singh L, Field MJ, Hill D: Second generation 'dipeptoid' CCK-B receptor antagonists: development of N-adamantyloxycarbonyl-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. J Med Chem 41: 38-45, 1998
28. Kikuko A, Kyoko I, Susumu O: Antisecretory and ulcer healing effects of S-0509, a novel CCK/gastrin receptor antagonist, in rats. Dig Dis Sci 44: 879-888, 1999
29. Lane A, Ivy AC, Ivy EK: Response of chronic fistula rat to histamine. Am J Physiol 192: 221-228, 1957
30. Ghosh MN, Schild HO: Continuous recording of acid gastric secretion in the rat. Br J Pharmacol 13: 54-61, 1958
31. Hendrie CA, Neill JC, Shepherd JK, Dourish CT: The effects of CCK-A and CCK-B antagonists on activity in the black/white exploration model of anxiety in mice. Physiol Behav 54: 689-693, 1993
32. Evangelista S, Maggi CA: Protection induced by cholecystokinin 8 in ethanol-induced gastric lesions is mediated by vagal capsaicin sensitive fibers and CCK-A receptors. Br J Pharmacol 102: 119-122, 1991
33. Evangelista S, Maggi CA, Meli A: Influence of peripherally administered peptides on ethanol-induced gastric ulcers in the rat. Gen Pharmacol 18: 647-649, 1987
34. Mercer DW, Cross JM, Barreto JC, Strobel NHP, Russell DH, Miller TA: Cholecystokinin is a potent protective agent against alcohol-induced gastric injury in the rat. Dig Dis Sci 40: 651-660, 1995
35. Berglindh T: Gastric glands and cells: Preparations and in vitro methods. Meth Enzymol 192: 93-97, 1990
36. Bastaki SMA, Chandranath I, Garner A: Comparison of five antisecretory agents acting via gastric H+/K+-ATPase. J Physiol (Paris) 94: 19-23, 2000
37. Graffner H, Ekelund M, Hakanson R: Anaesthetic agents suppress basal and stimulated gastric acid secretion: Are intramural neurons involved? Scand J Gastroenterol 26: 1200-1204, 1991
38. Bastaki SMA, Waton NG, Garner A: Effects of anaesthetic agents on basal and histamine-stimulated acid secretion in the fistula rat. Eur J Gastroenterol Hepatol 7: 1199-1202, 1995
39. Bastaki SMA, Waton NG: Effects of anaesthetics and trauma on stimulated gastric acid secretion in chronic fistula dogs. Clin Exp Pharmacol Physiol 23: 532-536, 1996
40. Koop I, Eissele R, Patberg Rosskopf B, Koop H, Arnold H: A new CCKB/gastrin receptor antagonist acts on the rat pancreas. Int J Pancreatol Resort 15: 215-222, 1994
41. Hill DR, Shaw TM, Graham W, Woodruff GN: Autoradiographical detection of cholecystokinin-A receptors in primate brain using 1251-Bolton Hunter CCK-8 and 3H-MK-329. J Neurosci 10: 1070-1081, 1990
42. Mcfarlane RJ, Bateson MC, Green JRB, O'Donoghue DP, Dronfield MW, Keeling PWN, Burke GJ, Dickinson RJ, Shreeve DR, Peers EM: Omeprazole provides quicker symptom relief and duodenal ulcer healing than ranitidine. Gastroenterology 98: 278-283, 1990
43. Okabe S, Miyake H, Awane Y: Cytoprotective effects of NC-1300 and omeprazole on HCl-ethanol-induced gastric lesions in rats. Jpn J Pharmacol 42: 123-133, 1986
44. Mattsson H, Andersson K, Larsson H: Omeprazole provides protection against experimentally induced gastric mucosal lesions. Eur J Pharmacol 91: 111-114, 1983
45. Konturek SJ, Brzozowski T, Radecki T: Protective action of omeprazole, a benzimidazoles derivative, on gastric mucosal damage by aspirin and ethanol in rats. Digestion 27: 159-164, 1983
46. Chandranath SI, Bastaki, SMA, Singh J: A comparative study on the activity of lansoprazole, omeprazole and PD-136,450 on acidified ethanol- and indomethacin-induced gastric lesions in the rat. Clin Exp Physiol Pharmacol 29: 173-180, 2002
47. +-dependent secretagogue stimulation in isolated rabbit gastric glands. Am J Physiol 239: G90-G94, 1980
48. 14C-aminopyrine accumulation by isolated canine parietal cells. Am J Physiol 238: G366-G375, 1980